Nano-Albumon (Human Serum Albumin)

Human Serum Albumin functions as a colloidal osmotic agent. By raising the oncotic pressure within the bloodstream, it draws fluid from the interstitial spaces into the vascular compartment, thereby expanding circulating blood volume and supporting hemodynamic stability in patients with fluid deficits or low endogenous albumin.

The dosage of Nano-Albumon is individualized and determined by the prescribing clinician based on the patient’s clinical condition, serum albumin level, and required volume expansion. Healthcare professionals calculate the appropriate volume and infusion rate according to established medical guidelines.

Safety data for Human Serum Albumin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Nano-Albumon provides oncotic pressure expansion, unlike crystalloid solutions that act primarily through volume. Compared with synthetic colloids, Human Serum Albumin has a lower risk of coagulopathy and renal impairment, but it is more expensive and requires careful handling to maintain sterility and protein integrity.

Nano-Albumon must be stored at 2‑8 °C in a refrigerator. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain is essential to preserve protein stability and efficacy.

Nano-Albumon is administered intravenously or subcutaneously by a qualified healthcare professional. The infusion should be given slowly, with continuous monitoring of vital signs, to avoid rapid shifts in plasma volume and reduce the risk of adverse reactions.

Serious risks include anaphylactic reactions, acute lung injury or pulmonary edema, thromboembolic events, hemolysis, and rare transmission of infectious agents. Prompt recognition and management of these events are critical, and patients should be observed closely during and after infusion.

Nano-Albumon is contraindicated in individuals with known hypersensitivity to human albumin products. Caution is advised for patients with severe cardiac or renal failure, uncontrolled hypertension, or those at high risk for thromboembolic disease, unless the benefits clearly outweigh the risks.